Gary Whelan

Gary holds a M.Sc. degree in Translational Medicine from Trinity College, Dublin, and a B.Sc. degree in Biochemistry from the National University of Ireland, Galway. Gary joined Eradigm in September 2023 as an Associate Consultant. He seeks to utilise his decade of educational and professional expertise in the life sciences industry to advance the implementation of cutting-edge translational research and bring it to market. He aims to help companies deliver beneficial bench-to-bedside products to impact patient care.

Gary has previously worked at a boutique life sciences consulting firm based in NYC. His role predominantly focused on oncology-based market opportunity assessments and portfolio strategy projects. He has extensive experience analysing target indications from multiple perspectives, including the competitive landscape, clinical trial benchmarks, FDA/EMA requirements, patient treatment architecture, reimbursement dynamics, company financials, and market positioning. Gary has worked with various pharmaceutical companies across different therapeutic areas and geographies, and he has a deep understanding of the oncological, Parkinson’s, MS, ALS, Asthma, and digital clinical markets.  

Gary has previously worked as a research scientist in the Yan lab at Columbia University Irving Medical Center. His research focused on building a 3D air-liquid-interface organoid culture platform to model complex diseases, such as colorectal cancer, and to understand the immunogenic mechanisms that drive celiac disease. He also delved into investigating the intricacies of the intestinal stem cell niche for therapeutic benefit.  

Outside of work, Gary likes to keep active with cycling, running, and skiing. He is passionate about travelling and exploring new cultures, and he aims to eventually visit all seven continents.